Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is conducting a clinical study titled ‘MagnetisMM-32’ to evaluate the effectiveness of a new drug, Elranatamab, for treating relapsed or refractory multiple myeloma (MM) in patients who have previously undergone treatment. This Phase 3 study aims to compare Elranatamab with other established combination therapies to determine its safety and efficacy.
The intervention involves administering Elranatamab as a subcutaneous injection. Participants in the control group will receive a combination of drugs including Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, or Carfilzomib, based on the doctor’s choice. These treatments are designed to manage MM symptoms and improve patient outcomes.
The study follows a randomized, parallel assignment model without masking, focusing primarily on treatment. This design allows for a direct comparison between the experimental and control groups to assess the new drug’s performance.
The study began on February 8, 2024, with an estimated completion date in 2025. The last update was submitted on July 1, 2025. These dates are crucial for tracking the study’s progress and anticipating results that could influence treatment protocols.
The outcome of this study could significantly impact Pfizer’s market position, potentially boosting its stock if Elranatamab proves effective. Investors should also consider the competitive landscape, as advancements in MM treatment could shift market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.